Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

From the start of treatment to the initiation of next-line treatment

Time from first occurrence of documented complete response or partial response to disease progression/relapse, or death from any cause for participants, whichever occurs first.

Time from the first occurrence of a documented complete response to the date of progression, relapse, or death from any cause, whichever occurs first.

Overall survival was defined as the time from the date of diagnosis to the date of death from any cause.

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Patient-reported outcomes using The European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30) .

Patient-reported outcomes using The European Organization for Research and Treatment of Cancer Quality of Life questionnaire including 20 items for patients with low-grade non-Hodgkin lymphoma (EORTC QLQ-NHL-LG20).